Events

Videos

Podcasts

Articles

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated. 

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Multidisciplinary Collaboration Plays Key Role in Pancreatic Cancer

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.

International Pancreatic Cancer Screening Program Displays Practicality

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma. 

Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Revisit Every OncLive On Air Episode from March 2024

A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer. 

Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Pancreatic Cancer | Specialty